High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing

Высокопроизводительная проточная микрофлюидная электропорация мРНК в первичные человеческие T-клетки для применения в производстве клеточной терапии
Michaela Welch, Deborah A. Flusberg, Charles A. Lissandrello, Jonathan R. Coppeta, Nerses J. Haroutunian, Ernest S. Kim, José A. L. Santos, Vienna L. Mott, Peter T. Hsi, Jordan Chesin, Aaron G. Stoddard, Andrew Czarnecki, Daniel K. Freeman, Jenna Leigh Balestrini, Vishal Tandon
2020-10-22

CRISPR/Cas9 gene editingcellular therapy manufacturingcontinuous-flow microfluidic electroporationmRNA deliveryprimary human T cells
Implementation of gene editing technologies such as CRISPR/Cas9 in the manufacture of novel cell-based therapeutics has the potential to enable highly-targeted, stable, and persistent genome modifications without the use of viral vectors. Electroporation has emerged as a preferred method for delivering gene-editing machinery to target cells, but a major challenge remaining is that most commercial electroporation machines are built for research and process development rather than for large-scale, automated cellular therapy manufacturing. Here we present a microfluidic continuous-flow electrotransfection device designed for precise, consistent, and high-throughput genetic modification of target cells in cellular therapy manufacturing applications. We optimized our device for delivery of mRNA into primary human T cells and demonstrated up to 95% transfection efficiency with minimum impact on cell viability and expansion potential. We additionally demonstrated processing of samples comprising up to 500 million T cells at a rate of 20 million cells/min. We anticipate that our device will help to streamline the production of autologous therapies requiring on the order of 10[Formula: see text]-10[Formula: see text] cells, and that it is well-suited to scale for production of trillions of cells to support emerging allogeneic therapies.
1
A continuous-flow microfluidic electrotransfection device was developed for precise, consistent, high-throughput genetic modification in cellular therapy manufacturing.
2
The device achieved up to 95% mRNA transfection efficiency in primary human T cells while minimally affecting viability and expansion potential.
3
The platform is intended to streamline autologous therapy manufacturing and offers scalability toward trillions of cells for emerging allogeneic therapies.
4
The system processed samples containing up to 500 million T cells at a rate of 20 million cells per minute.

primary human T cells undergoing continuous-flow microfluidic electroporation for mRNA delivery

high-throughput mRNA electrotransfection performance, including transfection efficiency, cell viability, expansion potential, and scalable processing capacity

Publication Details
Publication Date
2020-10-22
Journal
Publisher
ISSN
Cited by
87
Access Type
Author Information
Authors
Michaela Welch
Deborah A. Flusberg
Charles A. Lissandrello
Jonathan R. Coppeta
Nerses J. Haroutunian
Ernest S. Kim
José A. L. Santos
Vienna L. Mott
Peter T. Hsi
Jordan Chesin
Aaron G. Stoddard
Andrew Czarnecki
Daniel K. Freeman
Jenna Leigh Balestrini
Vishal Tandon
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%